Zacks Research Downgrades Repligen (NASDAQ:RGEN) to Hold

Repligen (NASDAQ:RGEN) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other brokerages have also commented on RGEN. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. Wolfe Research started coverage on Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target for the company. HSBC decreased their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research note on Tuesday, July 7th. Finally, Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $168.57.

Repligen Stock Performance

NASDAQ RGEN opened at $194.57 on Monday. The company has a market cap of $10.98 billion, a P/E ratio of 266.53, a P/E/G ratio of 3.54 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The business’s 50 day moving average price is $167.55 and its 200-day moving average price is $140.04. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $198.87.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period in the previous year, the firm earned $0.26 earnings per share. Repligen’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts predict that Repligen will post 2.06 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently made changes to their positions in the company. ABS Investment Management LLC acquired a new position in Repligen in the 2nd quarter valued at about $191,016,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Repligen during the second quarter worth about $52,000. Trust Co. of Vermont purchased a new stake in Repligen in the 2nd quarter valued at approximately $71,000. Harbor Investment Advisory LLC raised its stake in shares of Repligen by 198.9% during the 2nd quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company’s stock worth $71,000 after buying an additional 348 shares in the last quarter. Finally, Allworth Financial LP acquired a new stake in shares of Repligen in the 2nd quarter valued at approximately $71,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.